Media

All news HealthCap news Interviews

Heavily Pretreated, Relapsed and Relapsed Refractory Multiple Myeloma Patients Showed Significant Clinical Benefit, as Measured by Overall Response Rate and Progression Free Survival, when Treated with Melflufen and Dexamethasone

Creating Nordic leader in immuno oncology

Cerenis Therapeutics announces new Board members

Oncopeptides to Present Promising Phase I/ II Clinical Data at the European Hematology Association in Vienna, Austria, June 11 – 14 2015

Nasal Cavity Cooling for Migraine Trial, Utilizing BeneChill’s Proprietary Cooling System, Wins NHS’s 12th Bright Ideas in Health Awards

ULI HACKSELL, Ph.D., JOINS GLIONOVA AS CHAIRMAN OF THE BOARD

NORDIC NANOVECTOR: RESULTS FOR THE FIRST QUARTER 2015

Cerenis Therapeutics featured prominently at the INTERNATIONAL SYMPOSIUM ON ATHEROSCLEROSIS (IAS)

Onxeo Announces Final Data from Completed Phase II Trial of Validive® for the Prevention of Severe Oral Mucositis in Head and Neck Cancer Patients

NORDIC NANOVECTOR APPOINTS NEW SCIENTIFIC ADVISORY BOARD